XAIR - XAIR stock gains on data supporting inhaled nitric oxide as a COVID-19 therapy

Beyond Air (XAIR) has recorded the biggest intraday gain since November, after the clinical-stage health equipment company announced data from its LungFit PRO pilot study for inhaled nitric oxide in community-acquired viral pneumonia (CAVP), including COVID-19. Beyond Air (XAIR) is advancing its LungFit system as an NO generator and delivery system targeted at respiratory conditions, as well as solid tumors. The 40-subject trial, involving 39 hospitalized patients infected with COVID-19, was designed to compare NO inhalations in combination with standard supportive treatment (NO + SST) against standard supportive treatment alone (SST, control group). After 180-day follow up, Beyond Air (XAIR) said that the duration of oxygen treatment was significantly shorter for the patients who received NO. “We believe these results show that high concentration inhaled NO could be an effective treatment for patients hospitalized with COVID-19,” Chief Executive Steve Lisi noted. The clinical data were part of a presentation at

For further details see:

XAIR stock gains on data supporting inhaled nitric oxide as a COVID-19 therapy